Skip to content
Screener

Total Costs & Expenses at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$142.64M-27.0%
CVS Health logo
CVS HealthCVS
$101.39B+5.0%
Eos Energy Enterprises, Inc. logo
Eos Energy Enterprises, Inc.EOSE
$35.01M+6.4%
Brink's, Inc. logo
Brink's, Inc.BCO
$1.26B+8.4%
Lineage, Inc. logo
Lineage, Inc.LINE
$1.31B-1.5%
Macerich logo
MacerichMAC
$277.43M-1.1%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.68B-29.3%
Enterprise value$1.21B-38.3%
P/S30.7×-6.2×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Cost of revenue11,49120,16123,98141,990
Research and development89,614128,636177,510258,269
General and administrative41,53346,65376,124101,304
Total operating costs and expenses142,638195,450277,615401,563
Loss from operations(134,968)(176,227)(263,472)(367,595)
Other income (loss), net3,9624,33010,359(6,947)
Loss before income tax benefit(131,006)(171,897)(253,113)(374,542)
Income tax benefit14,604158

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s total costs & expenses?
Recursion Pharmaceuticals, Inc. (RXRX) reported total costs & expenses of $142.64M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s total costs & expenses changed year-over-year?
Recursion Pharmaceuticals, Inc.'s total costs & expenses decreased by 27.0% year-over-year, from $195.45M to $142.64M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total costs & expenses?
Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s total costs & expenses has grown at a 39.1% compound annual growth rate (CAGR), from $192.95M to $722.81M.
What does total costs & expenses mean?
Costs And Expenses as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.

Ask your AI about Recursion Pharmaceuticals, Inc.'s total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude